RBC Capital Maintains Sector Perform on Fulcrum Therapeutics, Raises Price Target to $10
Benzinga Newsdesk 11 months ago
NewsPrice TargetAnalyst Ratings
RBC Capital analyst Luca Issi maintains Fulcrum Therapeutics (NASDAQ:FULC) with a Sector Perform and raises the price target from $7 to $10.
RBC Capital analyst Luca Issi maintains Fulcrum Therapeutics (NASDAQ:FULC) with a Sector Perform and raises the price target from $7 to $10.